Darapladib for preventing ischemic events in stable coronary heart disease

New England Journal of Medicine

Volumn 370, Issue 18, 2014, Pages 1702-1711

  White, Harvey D ^a   Held, Claes ^b   Stewart, Ralph ^a   Tarka, Elizabeth ^c   Brown, Rebekkah ^c   Davies, Richard Y ^c   Budaj, Andrzej ^e   Harrington, Robert A ^f   Steg, P Gabriel ^g,h,j   Ardissino, Diego ^k   Armstrong, Paul W ^l   Avezum, Alvaro ⁿ   Aylward, Philip E ^p   Bryce, Alfonso ^q   Chen, Hong ^r   Chen, Ming Fong ^s   Corbalan, Ramon ^t   Dalby, Anthony J ^u   Danchin, Nicolas ⁱ   De Winter, Robbert J ^v   Denchev, Stefan ^w   Diaz, Rafael ^x   Elisaf, Moses ^y   Flather, Marcus D ^z,aa   Goudev, Assen R ^w   Granger, Christopher B ^d   Grinfeld, Liliana ^ab   Hochman, Judith S ^ac   Husted, Steen ^ad   Kim, Hyo Soo ^ae   Koenig, Wolfgang ^af   Linhart, Ales ^ag,ah   Lonn, Eva ^m   López Sendón, José ^ai   Manolis, Athanasios J ^aj   Mohler III, Emile R ^ak   Nicolau, José C ^o   Pais, Prem ^al   Parkhomenko, Alexander ^am   Pedersen, Terje R ^an   Pella, Daniel ^ao   Ramos Corrales, Marco A ^ap   Ruda, Mikhail ^aq   Sereg, Mátyás ^ar   Siddique, Saulat ^as   Sinnaeve, Peter ^at   Smith, Peter ^c   Sritara, Piyamitr ^au   Swart, Henk P ^av   Sy, Rody G ^aw   Teramoto, Tamio ^ax   Tse, Hung Fat ^ay   Watson, David ^c   Weaver, W Douglas ^az   Weiss, Robert ^ba   Viigimaa, Margus ^bb   Vinereanu, Dragos ^bc   Zhu, Junren ^bd   Cannon, Christopher P ^be   Wallentin, Lars ^b   more..

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UPPSALA UNIVERSITY   (Sweden)

^c GLAXOSMITHKLINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e GROCHOWSKI HOSPITAL   (Poland)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g INSERM   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j ROYAL BROMPTON HOSPITAL   (United Kingdom)

^k UNIVERSITY HOSPITAL OF PARMA   (Italy)

^l UNIVERSITY OF ALBERTA   (Canada)

^m MCMASTER UNIVERSITY   (Canada)

ⁿ INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^o UNIVERSITY OF SÃO PAULO   (Brazil)

^p FLINDERS UNIVERSITY   (Australia)

^q Cardiogolf Clinica El Golf   (Peru)

^r PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^s NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^t PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^u MILPARK HOSPITAL   (South Africa)

^v UNIVERSITY OF AMSTERDAM   (Netherlands)

^w UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^x Etudios Cardiologica Latin America Rosario   (Argentina)

^y UNIVERSITY OF IOANNINA   (Greece)

^z UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^aa NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^ab UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^ac NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^ad REGIONAL HOSPITAL WEST JUTLAND   (Denmark)

^ae Seoul National University Hospital   (South Korea)

^af UNIVERSITY HOSPITAL ULM   (Germany)

^ag CHARLES UNIVERSITY   (Czech Republic)

^ah CHARLES UNIVERSITY   (Czech Republic)

^ai HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^aj Asklepeion Hospital   (Greece)

^ak UNIVERSITY OF PENNSYLVANIA   (United States)

^al ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^am Ukranian Strazhesko Institute of Cardiology   (Ukraine)

^an UNIVERSITY OF OSLO   (Norway)

^ao P J AFÁRIK UNIVERSITY   (Slovakia)

^ap San Jose Satelite Hospital   (Mexico)

^aq INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^ar St George's Hospital   (Hungary)

^as Shaikh Zayed Postgraduate Medical Institute   (Pakistan)

^at UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^au MAHIDOL UNIVERSITY   (Thailand)

^av ST ANTONIUS HOSPITAL   (Netherlands)

^aw UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^ax Teikyo Academic Research Center   (Japan)

^ay UNIVERSITY OF HONG KONG   (Hong Kong)

^az HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^ba Maine Research Associates   (United States)

^bb TALLINN UNIVERSITY OF TECHNOLOGY   (Estonia)

^bc CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^bd FUDAN UNIVERSITY   (China)

^be BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DARAPLADIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHOLIPASE A2; PLACEBO; BENZALDEHYDE DERIVATIVE; OXIME; PHOSPHOLIPASE A2 INHIBITOR;

ABNORMAL FECES; ABNORMAL URINE COMPOSITION; AGE DISTRIBUTION; AGED; ANAPHYLAXIS; ARTICLE; ASTHMA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SKIN ODOR; URINE ODOR; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; HEART INFARCTION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; TREATMENT FAILURE;

AGED; BENZALDEHYDES; CORONARY ARTERY DISEASE; CORONARY DISEASE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OXIMES; PHOSPHOLIPASE A2 INHIBITORS; STROKE; TREATMENT FAILURE;

EID: 84899718423     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1315878     Document Type: Article

References (22)

1. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010;30:1282-92.
2. Häkkinen T, Luoma JS, Hiltunen MO, et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999;19:2909-17. (Pubitemid 30029817)
3. Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006;26:2523-9. (Pubitemid 44607475)
4. Carpenter KL, Dennis IF, Challis IR, et al. Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Lett 2001;505:357-63. (Pubitemid 32905477)
5. Hsieh CC, Yen MH, Liu HW, Lau YT. Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: in comparison with oxidized LDL. Atherosclerosis 2000;151:481-91.
6. MacPhee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999;338:479-87.
7. Shi Y, Zhang P, Zhang L, et al. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis 2007;191:54-62. (Pubitemid 46227429)
8. Takahashi M, Okazaki H, Ogata Y, Takeuchi K, Ikeda U, Shimada K. Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism. Atherosclerosis 2002;161:387-94. (Pubitemid 34219192)
9. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010;375:1536-44.
10. Blackie JA, Bloomer JC, Brown MJ, et al. The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2. Bioorg Med Chem Lett 2003;13:1067-70. (Pubitemid 36331801)
11. Wilensky RL, Shi Y, Mohler ER III, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008;14:1059-66.
12. Johnson JL, Shi Y, Snipes R, et al. Effect of darapladib treatment on endarterectomy carotid plaque lipoprotein-associated phospholipase A2 activity: a randomized, controlled trial. PLoS One 2014;9(2):e89034.
13. Serruys PW, García-García HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118:1172-82.
14. White H, Held C, Stewart R, et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J 2010;160:655-61.
15. Brosius FC III, Hostetter TH, Kelepouris E, et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney and Cardiovascular Disease Council, the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention, and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation 2006;114:1083-7. (Pubitemid 44358886)
16. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-9. (Pubitemid 43076437)
17. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010;304:1350-7.
18. Steg PG, Greenlaw N, Tardif JC, et al. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J 2012;33:2831-40.
19. O'Donoghue M, Morrow DA, Sabatine MS, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 2006;113:1745-52. (Pubitemid 43958467)
20. Ridker PM, MacFadyen JG, Wolfert RL, Koenig W. Relationship of lipoprotein-associated phospholipase A2 mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial. Clin Chem 2012;58:877-86.
21. 2 activity and mass in relation to vascular disease and nonvascular mortality. J Intern Med 2010;268:348-58.
22. White HD, Simes J, Stewart RA, et al. Changes in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study. J Am Heart Assoc 2013;2(5):e000360.